-
Mashup Score: 0EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis - 10 month(s) ago
Objective To develop evidence-based recommendations for the non-pharmacological management of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Methods A task force comprising 7 rheumatologists, 15 other healthcare professionals and 3 patients was established. Following a systematic literature review performed to inform the recommendations, statements were formulated, discussed…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications - 10 month(s) ago
Objectives To estimate the association of Janus kinase inhibitors (JAKi) with the incidence of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and methotrexate. Methods Systematic searches of databases were performed, to December 2022, to identify phase II/III/IV randomised clinical trials (RCTs) and long-term extension (LTE) studies of JAKi (tofacitinib,…
Source: Annals of the Rheumatic DiseasesCategories: Healthcare Professionals, Latest HeadlinesTweet-
Metanalysis 62 RCTs & 16 LTE RCTs looks at neoplasia risk in JAKi, TNFi, MTX, PBO. Total CA rate=1.15/100PYs in RCTs. No diff in all CA between JAKi vs PBO or JAKi vs MTX (IRR 0.77); but JAKi had more CA than TNFi (1.50; 1.16, 1.94) https://t.co/uRLJdO8A2j https://t.co/brNX6ZSfqq
-
-
Mashup Score: 12EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis - 10 month(s) ago
Objective To develop evidence-based recommendations for the non-pharmacological management of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Methods A task force comprising 7 rheumatologists, 15 other healthcare professionals and 3 patients was established. Following a systematic literature review performed to inform the recommendations, statements were formulated, discussed…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
EULAR recommendations for the non-pharmacological management of #SLE and #SSc 📕 patient education and self-management 🚭 cessation of smoking ❄️ avoidance of cold exposure 🤸 physical exercise and more... Read the full recommendations here 👇 https://t.co/PPmOMtEMeb
-
-
Mashup Score: 0
Background The optimal first-line treatment in early rheumatoid arthritis (RA) is debated. We compared clinical and radiographic outcomes of active conventional therapy with each of three biological treatments with different modes of action. Methods Investigator-initiated, randomised, blinded-assessor study. Patients with treatment-naïve early RA with moderate–severe disease activity were…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
🤔 #Certolizumab pegol, #abatacept, or #tocilizumab in early #rheumatoid #arthritis❓ ❗ CDAI remission rates compared to active conventional therapy: ◾ abatacept +20.1%, p<0.001 ◾ certolizumab +13.1%, p=0.021 ◾ tocilizumab +12.7%, p=0.030 https://t.co/jfgEoMyhk4 https://t.co/LTZIRsJjPY
-
-
Mashup Score: 3JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications - 10 month(s) ago
Objectives To estimate the association of Janus kinase inhibitors (JAKi) with the incidence of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and methotrexate. Methods Systematic searches of databases were performed, to December 2022, to identify phase II/III/IV randomised clinical trials (RCTs) and long-term extension (LTE) studies of JAKi (tofacitinib,…
Source: Annals of the Rheumatic DiseasesCategories: Healthcare Professionals, Latest HeadlinesTweet-
Metanalysis 62 RCTs & 16 LTE RCTs looks at neoplasia risk in JAKi, TNFi, MTX, PBO. Total CA rate=1.15/100PYs in RCTs. No diff in all CA between JAKi vs PBO or JAKi vs MTX (IRR 0.77); but JAKi had more CA than TNFi (1.50; 1.16, 1.94) https://t.co/aiJHQ5oPqt https://t.co/8MjJv728sh
-
-
Mashup Score: 6Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares - 10 month(s) ago
Objective Whereas genetic susceptibility for systemic lupus erythematosus (SLE) has been well explored, the triggers for clinical disease flares remain elusive. To investigate relationships between microbiota community resilience and disease activity, we performed the first longitudinal analyses of lupus gut-microbiota communities. Methods In an observational study, taxononomic analyses,…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
🚨 first longitudinal study to investigate relationship between microbiota and #SLE flares. 👉 expansions of Ruminococcus gnavus occurred during flares 👉 strains show common expression of a cell membrane-associated lipoglycan ❓ cause or consequence❓ https://t.co/EGFVyn0qld
-
-
Mashup Score: 2Outcomes following SARS-CoV-2 infection in individuals with and without inflammatory rheumatic diseases: a Danish nationwide cohort study - 10 month(s) ago
Objective In a setting with an extensive SARS-CoV-2 test strategy and availability of effective vaccines, we aimed to investigate if patients with inflammatory rheumatic diseases (IRD) face greater risk of contracting SARS-CoV-2 and have a worse prognosis of increased risk of hospitalisation, assisted ventilation and death compared with the general population. Methods This was a nationwide,…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
📣 Results from a Danish nationwide cohort study on #SARS-CoV-2 👉 Patients with #rheumatic diseases had higher risk of: ◾ hospitalisation ◾ severe #COVID-19 ◾ assisted ventilation ◾ death ✔️ 3rd vaccination--> hospitalisation and risk of death⬇️ https://t.co/rclGlcdaDp https://t.co/JXiCkJDuhj
-
-
Mashup Score: 0Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis - 10 month(s) ago
Objectives To compare the safety and effectiveness of biologic and conventional disease-modifying antirheumatic drugs (DMARDs) for immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA). Methods The retrospective multicentre observational study included patients with a diagnosis of ICI-IA treated with a tumour necrosis factor inhibitor (TNFi), interleukin-6 receptor inhibitor…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
#BWHRheumatology studies safety & effectiveness of biologic & conventional DMARDs for ICI-inflammatory arthritis (ICI-IA). Treating ICI-IA w/ a biologic DMARD assoc. w/ quicker arthritis control but may be assoc. w/ shorter time to cancer progression. https://t.co/Cu7gG4LjYb https://t.co/PJcnORVzGD
-
-
Mashup Score: 0
Introduction Current scientific evidence guiding the decision whether men with an active desire to become a father should be treated with methotrexate (MTX) remains controversial. We aimed to prospectively evaluate the testicular toxicity profile of MTX focusing on several markers of male fertility, including semen parameters and sperm DNA fragmentation index (sDFI). As a secondary outcome, we…
Source: Annals of the Rheumatic DiseasesCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @drdavidliew : Men trying to conceive were prev told to avoid MTX. Another myth busted Why? Spermatozoa lack the FPGS enzyme responsible for MTX-PG metabolism, the tiny amount of MTX-PG in sperm isn’t active. No quality issues! OP0224 #EULAR2023 https://t.co/i4WGmoWOwU)
-
-
Mashup Score: 1JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications - 10 month(s) ago
Objectives To estimate the association of Janus kinase inhibitors (JAKi) with the incidence of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and methotrexate. Methods Systematic searches of databases were performed, to December 2022, to identify phase II/III/IV randomised clinical trials (RCTs) and long-term extension (LTE) studies of JAKi (tofacitinib,…
Source: Annals of the Rheumatic DiseasesCategories: Healthcare Professionals, Latest HeadlinesTweet-
Metanalysis of 62 RCTs, 16 LTEs, 82 366 Pt-Yrs JAK exposure. JAKi malignancy incid rate = 1.15/100 PYs in RCTs (1.26/100PYs overall). Network meta-analyses show no diff betw JAK & PBO or MTX in NMSC, but signif increased malignancy risk (IRR 1.50) https://t.co/ANa7zYmhPx
-
Non-pharmacological management of #lupus & #SystemicSclerosis should ➡️Tailor to patients’ needs, expectations, preferences ➡️Based on shared-decision making ➡️Not substitute for pharmaceutical treatment when required 👉🏽https://t.co/Xt23WRMegi by @IoannisParodis et al @ARD_BMJ https://t.co/ZPcdkP5ycK